C-F5KOETTA
AI platform, senolytics, small molecules
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-F5KO
C-F5KOC-F5KOAI platform, senolytics, small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
ETTA AI platform, senolytics, small molecules
ETTA Biotechnology is developing longevity medicines intended to extend human lifespan and treat chronic diseases. Its SenoSmart platform evaluates molecules, gene mechanisms of action, tissue types, and criteria related to effectiveness, safety, metabolism, bioavailability, and clinical success. The company states that its first novel molecule lead safely and effectively clears senescent cells and reverses a marker of kidney aging and disease.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
ETTA — Early mechanism · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic